Synthesis and Antimicrobial Activities Evaluation of New Spiro[4.5]dec-2-enes Containing 1,2,4-Triazole, Piperidine and Sulfonamide Moieties

Hany Mahmoud Dalloul^{1,*}, Khaled A. El-nwairy², Ali Zayed Shorafa²,
Ahmed Sulyman Abu Samaha³

¹Department of Chemistry, Faculty of Applied Science, Alaqsa University of Gaza, Gaza Strip, Palestine

²Ministry of Education & Higher Education, South Remal, Gaza, Palestine

³Department of Biology, Faculty of Applied Science, Alaqsa University, Gaza, Palestine

Email address:

hmdalloul60@yahoo.com (H. M. Dalloul)

*Corresponding author

To cite this article:

Hany Mahmoud Dalloul, Khaled A. El-nwairy, Ali Zayed Shorafa, Ahmed Sulyman Abu Samaha. Synthesis and Antimicrobial Activities Evaluation of New Spiro[4.5]dec-2-enes Containing 1,2,4-Triazole, Piperidine and Sulfonamide Moieties. *American Journal of Heterocyclic Chemistry*. Vol. 3, No. 1, 2017, pp. 1-7. doi: 10.11648/j.ajhc.20170301.11

Received: October 28, 2016; **Accepted:** February 10, 2017; **Published:** March 1, 2017

Abstract: A new series of 1,2,4,8-tetraazaspiro[4.5]dec-2-enes containing 1,2,4-triazole, piperidine and sulfonamide moieties have been synthesized from the reaction of 4-piperidone benzoylhydrazones having 1-methyl, 1-benzyl, and 1-isopropyl groups with appropriate nitrilimines. The microanalysis and spectral data (IR, ¹H NMR, ¹³C NMR and MS) of the synthesized compounds are in full agreement with their molecular structure. The microbial features of the synthesized compounds were studied by a known method. Some of titled compounds exhibited significant antimicrobial activity on several strains of microbes.

Keywords: Nitrilimines, Piperidine, Sulfonamide, 1,2,4,8-tetraazaspiro[4.5]dec-2-ene

1. Introduction

The interest in the chemistry of hydrazoneyl halides is a consequence of the fact that they undergo a wide variety of reactions which provide routes to many of heterocyclic and spiro heterocyclic compounds [1-4]. Spiro heterocyclic compounds possess various pharmacological properties and hence their synthesis is of interest to organic chemists. Such compounds display pronounced antimicrobial [5], analgesic [6], anti-inflammatory [6], antimycobacterial [7], antifungal [8], antitumor [9, 10] and antiviral [9, 10] activities. Among these heterocycles, spiro azoles have been identified as privileged structures in medicinal chemistry and have attracted increasing interest in the recent years [11-14].

A survey of the literature has shown that compounds having azole derivatives to possess diverse biological activity and are widely used in a medicinal chemistry [15-18]. The 1,2,4-triazole derivatives has received a considerable attention in view of their diverse pharmacological activities

[19-22] such as antimicrobial [23, 24] sedative, anticonvulsant [25], anti-inflammatory properties [26] and anticancer agents. They are also use as intermediates in obtaining colour photosensitive materials as well as toners, inks and other photographic materials such as magenta coupler in a photosensitive emulsion layer [27-30]. The most developed procedure for construction of spirocompounds depends mainly on 1,3-dipolar cycloadditions to exocyclic double bonds [31]. Recently, we described a versatile and efficient one-pot synthesis of hexa and octaazadispiroheterocyclic compounds utilizing 1,4-cyclohexanedione oxime or methyl hydrazones and nitrilimines, generated in situ from the corresponding hydrazoneyl halides by the action of a suitable base [32, 33].

In continuation of our research studies dealing with the utility of hydrazoneyl halides for the synthesis of various heterocyclic ring and spiroheterocyclic systems via 1,3-dipolar cycloaddition methodology [34-40]. It was interest to study a facile synthesis of 1,2,4,8-tetraazaspiro[4.5]dec-2-

enes from the reaction of 1-substituted-4-piperidone benzoylhydrazones with hydrazonoyl halides having sulfonamide moiety in attempt to investigate their antimicrobial activities.

2. Material and Methods

2.1. Apparatus and Chemicals

Melting points were determined using an electro thermal melting temperature apparatus and are uncorrected. The IR spectra were measured as KBr pellets using a Satellite 3000 Mid infrared spectrometer. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker AM 300 MHz spectrometer at r. t. in DMSO- d_6 solution using tetramethylsilane (TMS) as internal reference. Chemical shifts are expressed in δ (ppm) downfield from TMS and coupling constants are in Hertz (Hz). Electron impact (EI) mass spectra were run on a Shimadzu GCMS-QP1000 EX spectrometer at 70 eV. Elemental analysis were carried out at micro analytical laboratory, Cairo University, Cairo, Egypt. 1-Methyl, 1-benzyl and 1-isopropyl-4-piperidone was purchased from Avocado Research Chemicals, England, and used without further purification. Hydrazonoyl chlorides 1 employed in this study, were prepared via direct coupling of the appropriate sulfa drug diazonium chloride with 3-chloroacetylacetone or phenacyl chloride or α -chloroacetoacetanilide or α -bromo-2-acetylfuran or α -bromo-2-acetylthiophene or ω -bromoacetophenone in ethanolic sodium acetate solution following standard procedures [41]. 1-substituted-4-piperidone benzoylhydrazones 3 were obtained by reacting the appropriate 1-substituted-4-piperidone with benzoylhydrazine in excess following reported procedures [37, 42].

2.2. Synthesis of 1,2,4,8-tetraazaspiro[4.5]dec-2-enes (General Procedure)

To a stirred solution of hydrazonoyl halides 1 (5 mmol) and 1-substituted-4-piperidone hydrazones 3 (10 mmol) in 1,4-dioxane (50-70 ml), triethylamine (5 mmol) in 1,4-dioxane (10 ml) dropwise added at room temperature. Stirring was continued to reaction completion for 12-16 hours (monitoring the reaction progress by TLC). The solvent was then removed under vacuum, and the residual solid was washed with water (100 ml) to get rid of the triethylamine salt. In some cases the residue was extracted with chloroform (3x30 ml) and the combined extracts were washed with water (50 ml), dried over anhydrous sodium sulfate. The solvent (CHCl_3) was evaporated in vacuum, and the crude product was triturated with ethanol (10-20 ml). The crude solid products were collected and recrystallized from appropriate solvents to afford the desired compounds 4a-u. The following compounds were prepared using this method:

3-Acetyl-4-benzoylamino-8-methyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4a: Yield 75%, m.p. 188-190°C (ethanol). IR, ν/cm^{-1} : 3380, 3347, 2365 (NH's), 1689, 1675 (C=O's), 1620 (C=N), 1347,

1156 (SO_2); ^1H NMR, δ/ppm : 11.61 (s, 1H, SO_2NH), 9.45 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 9H, Ar-H), 6.62 (d, 1H thiazole ring), 2.82-1.80 (m, 8H, 4 CH_2) 2.56 (s, 3H, CH_3CO), 2.41 (s, 3H, NCH_3); ^{13}C NMR (DMSO- d_6): δ/ppm 189.60 (C=O), 169.01 (N-C=O), 147.34 (C=N), 166.7-115.20 (Ar-C and thiazole-C), 91.12 (spiro carbon), 52.89 (2 CH_2), 46.60 (NCH_3), 32.20 (2 CH_2), 26.25 (CH_3). MS: (M^+ = 343); Anal. Calcd for $\text{C}_{18}\text{H}_{22}\text{N}_6\text{O}_3\text{S}_2$ (434.54): C 49.75%, H 5.10%, N 19.34%. Found: C 49.56%, H 4.98%, N 19.47%.

3-Acetyl-4-benzoylamino-8-isopropyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4b: Yield 72%, m.p. 193-195 °C (ethanol). IR, ν/cm^{-1} : 3377, 3345, 2362 (NH's), 1687, 1665 (C=O's), 1621 (C=N), 1346, 1154 (SO_2); ^1H NMR, δ/ppm : 11.64 (s, 1H, SO_2NH), 9.46 (s, 1H, CONH), 8.72 (d, 1H thiazole ring), 7.36-7.20 (m, 9H, Ar-H), 6.64 (d, 1H thiazole ring), 2.86-1.82 (m, 8H, 4 CH_2) 2.56 (s, 3H, CH_3CO), 2.43 (1H, m, CH), 1.25 (6H, d, 2 CH_3). ^{13}C NMR (DMSO- d_6): δ/ppm 189.60 (C=O), 169.05 (N-C=O), 147.34 (C=N), 166.7-115.20 (Ar-C and thiazole-C), 91.05 (spiro carbon), 52.87 (2 CH_2), 47.60 (NCH), 32.20 (2 CH_2), 27.80 (2 CH_3), 26.24 (CH_3). MS: (M^+ = 462); Anal. Calcd. for $\text{C}_{20}\text{H}_{26}\text{N}_6\text{O}_3\text{S}_2$ (462.60): C 51.93%, H 5.67%, N 18.17%. Found: C 52.18%, H 5.80%, N 18.05%.

3-Acetyl-4-benzoylamino-8-benzyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4c: Yield 75%, m.p. 176-178°C (ethanol). IR, ν/cm^{-1} : 3375, 3344, 2360 (NH's), 1689, 1665 (C=O's), 1622 (C=N), 1347, 1153 (SO_2); ^1H NMR, δ/ppm : 11.61 (s, 1H, SO_2NH), 9.44 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 14H, Ar-H), 6.62 (d, 1H thiazole ring), 3.26 (2H, s, CH_2Ph), 2.82-1.83 (m, 8H, 4 CH_2) 2.56 (s, 3H, CH_3CO). ^{13}C NMR (DMSO- d_6): δ/ppm 189.60 (C=O), 169.02 (N-C=O), 147.34 (C=N), 166.97-115.24 (Ar-C and thiazole-C), 91.10 (spiro carbon), 52.80 (2 CH_2), 50.10 (CH_2Ph), 32.22 (2 CH_2), 26.16 (CH_3). MS: (M^+ = 510); Anal. Calcd for $\text{C}_{24}\text{H}_{26}\text{N}_6\text{O}_3\text{S}_2$ (510.64): C 56.45%, H 5.13%, N 16.46%. Found: C 56.20%, H 5.02%, N 16.33%.

3-Acetyl-4-benzoylamino-8-methyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4d: Yield 70%, m.p. 182-184 °C (ethanol). IR, ν/cm^{-1} : 3380, 3346, 2360 (NH's), 1690, 1660 (C=O's), 1624 (C=N), 1344, 1152 (SO_2); ^1H NMR, δ/ppm : 11.65 (s, 1H, SO_2NH), 9.52 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 7.37-7.18 (m, 9H, Ar-H), 6.89 (t, 1H pyrimidine ring), 2.81-1.80 (m, 8H, 4 CH_2) 2.55 (s, 3H, CH_3CO). 2.40 (s, 3H, NCH_3) ppm. ^{13}C NMR (DMSO- d_6): δ = 189.82 (C=O), 169.10 (N-C=O), 147.62 (C=N), 167.90-110.32 (Ar-C and pyrimidine-C), 91.14 (spiro carbon), 53.10 (2 CH_2), 46.62 (NCH_3), 32.21 (2 CH_2), 26.24 (CH_3). MS: (M^+ = 429); Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{N}_7\text{O}_3\text{S}$ (429.50): C 53.13%, H 5.40%, N 22.83%. Found: C 52.90%, H 5.53%, N 22.96%.

3-Acetyl-4-benzoylamino-8-isopropyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4e: Yield 77%, m.p. 202-204 °C (methanol). IR, ν/cm^{-1} : 3370, 3342, 2364 (NH's), 1688, 1662 (C=O's), 1621 (C=N), 1340, 1151 (SO_2); ^1H NMR, δ/ppm : 11.65 (s, 1H, SO_2NH), 9.52 (s,

1H, CONH), 8.86 (d, 2H pyrimidine ring), 7.37-7.18 (m, 9H, Ar-H), 6.89 (t, 1H pyrimidine ring), 2.86-1.83 (m, 8H, 4CH₂), 2.56 (s, 3H, CH₃CO) 2.35 (m, 1H, CH), 1.26 (s, 6H, 2CH₃); ¹³C NMR (DMSO-d₆): δ = 189.76 (C=O), 169.05 (N-C=O), 147.66 (C=N), 167.87-110.23 (Ar-C and pyrimidine-C), 91.10 (spiro carbon), 53.12 (2CH₂), 47.60 (CH), 32.20 (2CH₂), 27.45 (2CH₃). MS: (M⁺ = 457); Anal. Calcd for C₂₁H₂₇N₇O₃S (457.56): C 55.13%, H 5.95%, N 21.43%. Found: C 54.90%, H 6.05, N 21.30%.

3-Acetyl-4-benzoylamino-8-benzyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4f: Yield 75%, m.p. 216-218 °C (methanol). IR, ν/cm⁻¹: 3378, 3344, 2358 (NH's), 1689, 1662 (C=O's), 1620 (C=N), 1345, 1150 (SO₂); ¹H NMR, δ/ppm: 11.65 (s, 1H, SO₂NH), 9.48 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 7.37-7.18 (m, 14H, Ar-H), 6.89 (t, 1H pyrimidine ring), 3.25 (s, 2H, PhCH₂), 2.86-1.83 (m, 8H, 4CH₂), 2.56 (s, 3H, CH₃CO). ¹³C NMR (DMSO-d₆): δ = 189.62 (C=O), 169.10 (N-C=O), 147.64 (C=N), 167.90-110.32 (Ar-C and pyrimidine-C), 91.12 (spiro carbon), 53.16 (2CH₂), 50.05 (PhCH₂), 32.24 (2CH₂), 26.21 (CH₃). MS: (M⁺ = 505); Anal. Calcd. for C₂₅H₂₇N₇O₃S (505.60): C 59.39%, H 5.38%, N 19.39%. Found: C 59.60%, H 5.26%, N 19.27%.

3-Benzoyl-4-benzoylamino-8-methyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4g: Yield 72%, m.p. 234-236 °C (methanol). IR, ν/cm⁻¹: 3367, 3342, 2357 (NH's), 1655, 1660 (C=O's), 1615 (C=N), 1346, 1152 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.43 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 14H, Ar-H), 6.62 (d, 1H thiazole ring), 2.82-1.83 (m, 8H, 4CH₂), 2.36 (s, 3H, NCH₃). ¹³C NMR (DMSO-d₆): δ/ppm 184.64 (Ar-C=O), 168.85 (N-C=O), 147.78 (C=N), 167.27-115.21 (Ar-C and thiazole-C), 90.85 (spiro carbon), 53.102 (2CH₂), 46.65 (NCH₃), 32.10 (2CH₂). MS: (M⁺ = 496); Anal. Calcd for C₂₃H₂₄N₆O₃S₂ (496.61): C 55.63%, H 4.87%, N 16.92%. Found: C 55.40%, H 4.76%, N 17.06%.

3-Benzoyl-4-benzoylamino-8-isopropyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4h: Yield 68%, m.p. 225-227 °C (ethanol). IR, ν/cm⁻¹: 3365, 3341, 2355 (NH's), 1656, 1661 (C=O's), 1612 (C=N), 1345, 1152 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.41 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 14H, Ar-H), 6.62 (d, 1H thiazole ring), 2.90-1.68 (m, 8H, 4CH₂), 2.42 (s, 3H, CH), 1.3 (s, 6H, 3CH₃); ¹³C NMR (DMSO-d₆): δ/ppm 184.60 (Ar-C=O), 168.56 (N-C=O), 147.84 (C=N), 167.17-115.14 (Ar-C and thiazole-C), 90.90 (spiro carbon), 53.20 (2CH₂), 47.60 (CH), 31.80 (2CH₂), 27.46 (2CH₃). MS: (M⁺ = 524); Anal. Calcd for C₂₅H₂₈N₆O₃S₂ (524.67): C 57.23%, H 5.38%, N 16.02%. Found: C 57.50%, H 5.50%, N 15.90%.

3-Benzoyl-4-benzoylamino-8-benzyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4i: Yield 66%, m.p. 213-215 °C (ethanol). IR, ν/cm⁻¹: 3365, 3338, 2356 (NH's), 1654, 1665 (C=O's), 1614 (C=N), 1344, 1153 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.40 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 19H, Ar-H), 6.62 (d, 1H thiazole ring), 3.36 (s, 2H, PhCH₃), 2.82-

1.83 (m, 8H, 4CH₂). ¹³C NMR (DMSO-d₆): δ/ppm 184.52 (Ar-C=O), 168.72 (N-C=O), 147.81 (C=N), 167.12-115.18 (Ar-C and thiazole-C), 90.82 (spiro carbon), 53.10 (2CH₂), 50.05 (PhCH₂), 31.86 (2CH₂). MS: (M⁺ = 572); Anal. Calcd for C₂₉H₂₈N₆O₃S₂ (572.71): C 60.82%, H 4.93%, N 14.67%. Found: C 61.06%, H 5.05%, N 14.55%.

4-Benzoylamino-8-methyl-3-phenylaminocarbonyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetra-azaspiro[4.5]-dec-2-ene 4j: Yield 72%, m.p. 238-240°C (ethanol). IR, ν/cm⁻¹: 3368, 3340, 2354 (NH's), 1665, 1670 (C=O's), 1615 (C=N), 1345, 1144 (SO₂); ¹H NMR, δ/ppm: 11.72 (s, 1H, SO₂NH), 9.86 (1H, s, Ph-NH), 9.47 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 14H, Ar-H), 6.62 (d, 1H thiazole ring), 2.92-1.65 (m, 8H, 4CH₂), 2.40 (s, 3H, NCH₃). ¹³C NMR (DMSO-d₆): δ/ppm: 168.62 (N-C=O), 159.80 (amide C=O), 147.37 (C=N), 166.70-115.22 (Ar-C and thiazole-C), 90.12 (spiro carbon), 52.89 (2CH₂), 46.60 (NCH₃), 31.94 (2CH₂). MS: (M⁺ = 511); Anal. Calcd for C₂₃H₂₅N₇O₃S₂ (511.63): C 54.00%, H 4.93%, N 19.19%. Found: C 53.77%, H 5.05%, N 19.30%.

4-Benzoylamino-8-benzyl-3-phenylaminocarbonyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetra-azaspiro[4.5]-dec-2-ene 4k: Yield 70%, m.p. 229-231 °C (ethanol). IR, ν/cm⁻¹: 3366, 3347, 2356 (NH's), 1660, 1668 (C=O's), 1618 (C=N), 1342, 1150 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.88 (1H, s, Ph-NH), 9.48 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 7.38-7.21 (m, 19H, Ar-H), 6.62 (d, 1H thiazole ring), 3.40 (s, 2H PhCH₂), 2.86-1.84 (m, 8H, 4CH₂); ¹³C NMR (DMSO-d₆): δ/ppm: 168.53 (N-C=O), 159.56 (amide C=O), 147.34 (C=N), 166.67-115.23 (Ar-C and thiazole-C), 89.95 (spiro carbon), 52.87 (2CH₂), 49.78 (PhCH₂), 31.90 (2CH₂). MS: (M⁺ = 587); Anal. Calcd for C₂₉H₂₉N₇O₃S₂ (587.73): C 74.97%, H 6.29%, N 14.57%. Found: C 75.22%, H 6.17%, N 14.68%.

4-Benzoylamino-8-Isopropyl-3-phenylaminocarbonyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4l: Yield 75%, m.p. 234-236°C (methanol). IR, ν/cm⁻¹: 3370, 3345, 2357 (NH's), 1665, 1672 (C=O), 1619 (C=N), 1348, 1153 (SO₂); ¹H NMR, δ/ppm: 11.60 (s, 1H, SO₂NH), 9.84 (s, 1H, PhNH), 9.45 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 7.37-7.18 (m, 14H, Ar-H), 6.89 (t, 1H pyrimidine ring), 2.41 (s, H, CH), 1.29 (s, 6H, 2CH₃); ¹³C NMR (DMSO-d₆): δ/ppm: 168.80 (N-C=O), 159.65 (amide C=O), 143.6 (C=N), 167.9-110.3 (Ar-C and pyrimidine-C), 89.97 (spiro carbon), 52.90 (2CH₂), 47.50 (CH), 31.80 (2CH₂), 27.44 (2CH₃). MS: (M⁺ = 534); Anal. Calcd for C₂₆H₃₀N₈O₃S (534.64): C 58.41%, H 5.66%, N 20.96%. Found: C 58.65%, H 5.75%, N 21.10%.

4-Benzoylamino-8-benzyl-3-phenylaminocarbonyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]-dec-2-ene 4m: Yield 74%, m.p. 242-244 °C (ethanol). IR, ν/cm⁻¹: 3372, 3347, 2359 (NH's), 1665, 1670 (C=O), 1613 (C=N), 1345, 1155 (SO₂); ¹H NMR, δ/ppm: 11.60 (s, 1H, SO₂NH), 9.84 (s, 1H, PhNH), 9.46 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 7.37-7.18 (m, 14H, Ar-H), 6.89 (t, 1H pyrimidine ring), 3.41 (s, 2H, PhCH₂); ¹³C NMR (DMSO-d₆): δ/ppm: 168.65 (N-C=O), 159.68 (amide C=O), 146.89

(C=N), 167.92-110.34 (Ar-C and pyrimidine-C), 89.96 (spiro carbon), 52.96 (2CH₂), 49.60 (PhCH₂), 31.78 (2CH₂). MS: (M⁺ = 582); Anal. Calcd for C₃₀H₃₀N₈O₃S (582.69): C 61.84%, H 5.19%, N 19.23%. Found: C 62.10%, H 5.06%, N 19.34%.

4-Benzoylamino-3-(2-furyl)-8-methyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4n: Yield 63%, m.p. 193-195 °C (methanol). IR, ν/cm⁻¹: 3375, 3337, 2361 (NH's), 1660, 1667 (C=O's), 1620 (C=N), 1351, 1154 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.42 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 8.23-7.22 (m, 12H, Ar-H), 6.62 (d, 1H thiazole ring), 2.84-1.81 (m, 8H, 4CH₂), 2.34 (s, 3H, NCH₃); ¹³C NMR (DMSO-d₆): δ/ppm 173.68 (Ar-C=O), 169.24 (N-C=O), 147.30 (C=N), 166.65-115.16 (Ar-C and thiazole-C), 90.42 (spiro carbon), 52.90 (2CH₂), 46.68 (NCH₃), 31.78 (2CH₂). MS: (M⁺ = 486); Anal. Calcd for C₂₁H₂₂N₆O₄S₂ (486.58): C 51.84%, H 4.56%, N 17.27%. Found: C 52.11%, H 4.70%, N 17.41%.

4-Benzoylamino-3-(2-furyl)-8-isopropyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4o: Yield 65%, m.p. 210-212 °C (methanol). IR, ν / c m⁻¹ : 3370, 3335, 2360 (NH's), 1662, 1669 (C=O's), 1618 (C=N), 1349, 1151 (SO₂); ¹H NMR, δ/PPM: 11.61 (s, 1H, SO₂NH), 9.43 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 8.23-7.24 (m, 12H, Ar-H), 6.62 (d, 1H thiazole ring), 2.86-1.83 (m, 8H, 4CH₂), 2.38 (s, 1H, CH), 1.30 (s, 6H, 2CH₃). ¹³C NMR (DMSO-d₆): δ/ppm 173.54 (Ar-C=O), 169.15 (N-C=O), 147.34 (C=N), 166.74-115.20 (Ar-C and thiazole-C), 90.62 (spiro carbon), 52.91 (2CH₂), 47.24 (CH), 31.85 (2CH₂), 27.46 (2CH₃). MS: (M⁺ = 514); Anal. Calcd for C₂₃H₂₆N₆O₄S₂ (514.63): C 53.68%, H 5.09%, N 16.33%. Found: C 53.45%, H 4.97%, N 16.22%.

4-Benzoylamino-8-benzyl-3-(2-furyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4p: Yield 62%, m.p. 204-206 °C (ethanol). IR, ν/cm⁻¹: 3372, 3340, 2356 (NH's), 1665, 1670 (C=O's), 1616 (C=N), 1345, 1147 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.45 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 8.26-7.23 (m, 12H, Ar-H), 6.62 (d, 1H thiazole ring), 3.36 (s, 2H, PhCH₂), 2.83-1.81 (m, 8H, 4CH₂); ¹³C NMR (DMSO-d₆): δ/ppm 173.65 (Ar-C=O), 169.27 (N-C=O), 147.34 (C=N), 166.7-115.20 (Ar-C and thiazole-C), 90.50 (spiro carbon), 52.89 (2CH₂), 49.87 (PhCH₂), 32.20 (2CH₂). MS: (M⁺ = 562); Anal. Calcd for C₂₇H₂₆N₆O₄S₂ (562.67): C 57.64%, H 4.66%, N 14.94%. Found: C 57.85%, H 4.53%, N 15.05%.

4-Benzoylamino-8-methyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-3-(2-thienyl)-1,2,4,8-tetraaza-spiro[4.5]dec-2-ene 4q: (1.33 g, 64%), m.p. 213-215 °C (ethanol). IR, ν/cm⁻¹: 3368, 3346, 2360 (NH's), 1660, 1667 (C=O's), 1615 (C=N), 1346, 1153 (SO₂); ¹H NMR, δ/ppm: 11.60 (s, 1H, SO₂NH), 9.44 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 8.36-7.16 (m, 12H, Ar-H), 6.89 (t, 1H pyrimidine ring), 2.86-1.83 (m, 8H, 4CH₂), 2.31 (s, 3H, NCH₃); ¹³C NMR (DMSO-d₆): δ = 174.54 (Ar-C=O), 169.28 (N-C=O), 147.63 (C=N), 167.9-110.37 (Ar-C and pyrimidine-C), 89.95 (spiro carbon), 52.70 (2CH₂), 46.64 (CH₃), 31.90 (2CH₂). MS: (M⁺ = 497); Anal. Calcd for C₂₂H₂₃N₇O₃S₂ (497.60): C 53.10%, H

4.66%, N 19.70%. Found: C 52.87%, H 4.78%, N 19.57%.

4-Benzoylamino-8-isopropyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-3-(2-thienyl)-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4r: Yield 66%, m.p. 221-223 °C (ethanol). IR, ν/cm⁻¹: 3374, 3347, 2362 (NH's), 1660, 1668 (C=O's), 1613 (C=N), 1347, 1151 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.47 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 8.38-7.16 (m, 12H, Ar-H), 6.62 (d, 1H thiazole ring), 2.82-1.83 (m, 8H, 4CH₂), 2.33 (s, 1H, CH), 1.26 (s, 6H, 2CH₃); ¹³C NMR (DMSO-d₆): δ/ppm 174.60 (Ar-C=O), 169.18 (N-C=O), 147.34 (C=N), 166.76-115.20 (Ar-C and thiazole-C), 89.90 (spiro carbon), 52.80 (2CH₂), 47.20 (CH), 32.20 (2CH₂), 27.46 (2CH₃). MS: (M⁺ = 530); Anal. Calcd for C₂₃H₂₆N₆O₃S₃ (530.69): C 52.06%, H 4.94%, N 15.84%. Found: C 51.83%, H 5.10%, N 15.72%.

4-Benzoylamino-8-benzyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-3-(2-thienyl)-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4s: Yield 65%, m.p. 207-209 °C (ethanol). IR, ν/cm⁻¹: 3370, 3341, 2356 (NH's), 1660, 1665 (C=O's), 16015 (C=N), 1342, 1147 (SO₂); ¹H NMR, δ/ppm: 11.60 (s, 1H, SO₂NH), 9.43 (s, 1H, CONH), 8.86 (d, 2H pyrimidine ring), 8.37-7.18 (m, 12H, Ar-H), 6.89 (t, 1H pyrimidine ring), 3.40 (s, 2H, PhCH₂), 2.90-1.80 (8H, m, 4CH₂); ¹³C NMR (DMSO-d₆): δ = 174.56 (Ar-C=O), 169.16 (N-C=O), 147.36 (C=N), 167.92-110.37 (Ar-C and pyrimidine-C), 89.85 (spiro carbon), 53.00 (2CH₂), 49.94 (PhCH₂), 31.87 (2CH₂). MS: (M⁺ = 573); Anal. Calcd for C₂₈H₂₇N₇O₃S₂ (573.70): C 58.62%, H 4.74%, N 17.09%. Found: C 58.40%, H 4.88%, N 16.95%.

4-Benzoylamino-8-methyl-3-(2-naphthyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraazaspiro[4.5]dec-2-ene 4t: Yield 58%, m.p. 257-259 °C (ethanol). IR, ν/cm⁻¹: 3368, 3342, 2358 (NH's), 1650, 1665 (C=O's), 1597 (C=N), 1350, 1156 (SO₂); ¹H NMR, δ/ppm: 11.61 (s, 1H, SO₂NH), 9.41 (s, 1H, CONH), 8.76 (d, 1H thiazole ring), 8.83-7.25 (m, 16H, Ar-H), 6.62 (d, 1H thiazole ring), 3.00-1.81 (m, 8H, 4CH₂), 2.36 (s, 3H, NCH₃); ¹³C NMR (DMSO-d₆): δ/ppm 182.60 (Ar-C=O), 168.86 (N-C=O), 147.34 (C=N), 166.7-115.20 (Ar-C and thiazole-C), 90.12 (spiro carbon), 89.66 (spiro carbon), 52.87 (2CH₂), 46.60 (NCH₃), 31.80 (2CH₂). MS: (M⁺ = 546); Anal. Calcd for C₂₇H₂₆N₆O₃S₂ (546.67): C 59.32%, H 4.79%, N 15.37%. Found: C 59.10%, H 4.92%, N 15.50%.

4-Benzoylamino-8-methyl-3-(2-naphthyl)-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4,8-tetraaza-spiro[4.5]dec-2-ene 4u: Yield 56%, m.p. 263-265 °C (ethanol). IR, ν/cm⁻¹: 3372, 3343, 2358 (NH's), 1662, 1652 (C=O's), 1614 (C=N), 1351, 1158 (SO₂); ¹H NMR, δ/ppm: 12.60 (s, 1H, SO₂NH), 9.40 (s, 1H, CONH), 8.82 (d, 2H pyrimidine ring), 8.87-7.28 (m, 16H, Ar-H), 6.89 (t, 1H pyrimidine ring), 3.01-1.80 (m, 8H, 4CH₂), 2.38 (s, 2H, NCH₃) ppm. ¹³C NMR (DMSO-d₆): δ/ppm 182.62 (Ar-C=O), 168.82 (N-C=O), 147.60 (C=N), 167.91-110.33 (Ar-C and pyrimidine-C), 89.68 (spiro carbon), 53.00 (2CH₂), 46.64 (CH₃), 32.10 (2CH₂). MS: (M⁺ = 541); Anal. Calcd for C₂₈H₂₇N₇O₃S (541.64): C 62.09%, H 5.02%, N 18.10%. Found: C 61.85%, H 5.18%, N 18.06%.

2.3. Screening for Antimicrobial Activity

Antimicrobial activity screening of the synthesized

compounds was determined by the agar dilution technique as recommended by the Clinical and Laboratory Standard Institute (CLSI) [30]. The tested compounds were dissolved in dimethyl sulfoxide (DMSO). An inoculum of about 1.5×10^8 colony forming unit per spot was applied to the surfaces of Mueller–Hinton agar plates containing graded concentrations of the respective compound; plates were incubated at 37 °C for 18 h. The spot with the lowest concentration of compound showing no growth was defined as the minimum inhibitory concentration (MIC). All organisms used in this study were standard strains were obtained from the Microbiology laboratory (Al-Aqsa University) and included bacterial strain such as *Enterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella spp*, *Proteus spp*, and fungi strain such as *Aspergillus niger*, *Candida albicans*. The MIC of Tetracycline and fluconazole was determined concurrently as reference for antibacterial and antifungal activities, respectively (Table 1). Control DMSO was carried out with each experiment.

3. Results and Discussion

The nitrilimines **2** employed in this study was generated in situ from the corresponding hydrazonoyl halides **1** by the action of a suitable base as shown in Figure 1. The treatment of the resulting non-isolable nitrilimines **2**, 1,3-dipole, with appropriate 1-methyl, 1-isopropyl and 1-benzyl-4-piperidone benzoyl-hydrazones **3** in 1,4-dioxane or tetrahydrofuran in presence of triethylamine as a base, gave in each case a single product that proved to be the respective 1,3,4-trisubstituted 1,2,4-spirotriazole derivatives **4a-u**, as cycloaddition products through the 1,3-dipolar cycloaddition of nitrilimines **2** to the exocyclic double bond (N=C) of benzoylhydrazone **3** instead of the spirotriazine cyclocondensation products **5a-u** (Figure 1). The purity of obtained compounds was controlled by TLC and elemental analysis. Both the analytical and spectral data (IR, ^1H NMR, ^{13}C NMR and mass spectra) of the synthesized spirotriazoles were in full agreement with the proposed structures.

Figure 1. Synthetic pathway of 1,2,4,8-tetraazaspiro[4.5]dec-2-enes **4a-u**.

3.1. Spectroscopical Data of Spiro Compounds **4a-u**

The characterization data of synthesized spiro compounds **4a-u** are given in the experimental section. These compounds gave satisfactory analysis for the proposed structures which are confirmed on the bases of their spectroscopical data. The IR spectra showed the strong absorption band of CONH of the triazole ring in the region $3380\text{--}3360\text{ cm}^{-1}$, in addition to, characteristic band of SO_2NH in the region of $3340\text{--}3220\text{ cm}^{-1}$, (Ar-C=O) at about $1680\text{--}1660\text{ cm}^{-1}$ and bands at 1350 , 1150 cm^{-1} attributed to SO_2 of sulfonamide group. In the ^1H

NMR spectra, a characteristic signal due to the PhCONH proton of the triazole ring appeared at 9.50–9.40 ppm. The NH of the tetrazine structures **5a-u** if formed is expected to resonate at about 5–4 ppm [43]. The signals at 8.70, 6.60 ppm and 8.40, 6.80 ppm are attributed to thiazole and pyrimidine protons, respectively. Also, the spectra exhibit a characteristic singlet at 11.6–11.5 ppm and due to SO_2NH proton. The structures of compounds **4a-u** were further confirmed by ^{13}C NMR spectra, which account for the different carbons of these spirotriazoles. The signal at 89–91 ppm was attributed to the C-5 (spiro carbon) of the triazole

ring is of special significance. This assignment is in good agreement with literature data for quaternary carbons flanked by two nitrogen atoms in five-membered heterocycles [36,37,41], which provides strong evidence in support of the structures 4a-u rather than the six-membered structures 5a-u, which is expected to have a spiro carbon at about 60-70 ppm. The signal at about 147-146 ppm was attributed to the C-3 carbon of the triazole ring, and this is similar to reported values of azomethine carbons of five-membered heterocycles [37]. The electron impact (EI) mass spectra displayed the correct molecular ions (M^+) in accordance with the suggested structures. The base peak in all these compounds 4a-u was that of the conjugated vinyl triazole cation this fragmentation pattern is well known for cycloalkanes [44].

3.2. Antimicrobial Activity

Most of the synthesized compounds were screened in vitro for their antimicrobial activity against a variety of bacterial

strains such as *Enterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella spp*, *Proteus spp*, and fungi such as *Aspergillus niger*, *Candida albicans*, employing the nutrient agar disc diffusion method [30] at 1-100 mg/ml concentration in dimethyl sulfoxide (DMSO) which used as solvent control, by measuring the average diameter of the inhibition zone in mm. The results are given in Table 1.

All the experiments were carried out in triplicate. The results showed that all the tested compounds exhibited good degree of activity against different strains of bacteria and fungi compared with well-known antibacterial and antifungal substances such as tetracycline and fluconazole respectively. According to National Committee for Clinical Laboratory Standards (NCCLS, 2004) methodology, zones of inhibition for tetracycline and fluconazole < 14 mm were considered resistant, between 15 and 18 mm were considered weakly sensitive and > 19 mm were considered sensitive. The presence of sulfonamide moieties showed a better spectrum of activity than the reference drug.

Table 1. Antimicrobial screening results of the tested compounds*.

Comp. No.	Antibacterial activity				Antifungal activity		
	Enter.	E. coli	S. aureus	K. spp	P. spp	C. alb.	A. niger
4a	16	18	16	16	15	19	18
4b	18	19	14	15	17	20	19
4c	17	14	15	17	14	18	18
4d	16	19	17	18	15	20	19
4e	17	17	17	19	13	19	19
4f	15	14	15	18	16	17	18
4g	19	16	14	15	19	16	15
4h	15	18	13	16	15	14	17
4i	16	16	17	14	14	18	16
4j	14	14	16	15	16	16	17
4k	16	17	14	13	15	17	15
4l	17	15	13	15	17	18	14
4m	19	17	18	19	18	19	18
4n	17	15	15	16	15	16	16
4o	19	19	14	16	19	17	17
4q	17	20	18	17	18	14	18
4r	16	18	16	15	18	15	19
4s	15	17	18	17	16	14	16
4u	19	18	19	16	19	16	18
DMSO	--	--	--	--	--	--	--

*Calculated as average of three values.

Enter. = Enterococci, E. coli = Escherichia coli, S. aureus = Staphylococcus aureus, K. spp = Klebsiella spp, P. spp = Proteus spp, C. alb. = Candida albicans, A. niger = Aspergillus niger.

4. Conclusion

The reaction of nitrilimines 2 with 4-piperidone benzoylhydrazones 3 leads to formation of novel heterocyclic spirotriazoles 4a-u containing 1,2,4-triazole, piperidine and sulfonamide moieties and evaluated for antibacterial, and antifungal activities. From the screening results, it found to possess various antimicrobial activities towards all the microorganisms tested. The results confirm that, the antimicrobial activity is strongly dependent on the nature of the substituents on triazole nucleus. The pyrimidinyl, thiazolyl derivatives generally led to improvements in activity against both bacteria and fungi. The present study can lead medicinal chemists to design and synthesize similar

compounds with enhanced biological potency in future.

Acknowledgements

The authors are great thankful to the Qatar Charity for the financial support of this research through Ibath grant.

References

- [1] Sayed, A. R. *Tetrahedron* 2012, 68(13), 2784-2789.
- [2] Sayed, A. R.; Wiggins, J. S. *J. Appl. Poly. Sci.* 2011, 120(2), 623-630.
- [3] Sayed, A. R. *Tetrahedron Lett.* 2010, 51, 4490-4493.

- [4] Sayed, A. R.; Wiggins, J. S. *Polymer* 2008, 49(9), 2253-2259.
- [5] G. Periyasami, R. Raghunathan, G. Surendiran, N. Mathivanan, *Eur. J. Med. Chem.*, 2009, 44, 959.
- [6] K. Amin, M. Kamel, M. Anwar, M. Khedr, Y. M. Syamb, *Eur. J. Med. Chem.*, 2010, 45, 2117.
- [7] R. R. Kumar, S. Perumal, S. C. Manju, P. Bhatt, P. Yogeeswari and D. Sriram, *Bioorg. Med. Chem. Lett.*, 2009, 19, 3461.
- [8] A. Dandia, R. Singh, S. Khaturia, C. Merienne, G. Morgant and A. Loupy, *Bioorg. Med. Chem.*, 2006, 14, 2409.
- [9] G. Lang, A. Pinkert, J. W. Blunt and M. H. G. Munro, *J. Nat. Prod.*, 2005, 68, 1796.
- [10] C. A. Maier and B. Wuensch, *J. Med. Chem.*, 2002, 45, 438.
- [11] M. Wolf, A. A. Mascifffi, US Patent, 1968, 395, 156; *Chem. Abstr.*, 1988, 69, 96504r.
- [12] H. C. Rohm, *British Patent*, 1962, 913, 937; *Chem. Abstr.* 1963, 59, 577f.
- [13] G. Winters and N. D. Mola, German Patent, 1975, 2442, 667; *Chem. Abstr.* 1975, 83, 28096.
- [14] M. J. Kornet and A. P. Thio, *J. Med. Chem.*, 1976, 19, 892.
- [15] S. Gurvinder, Maninderjit K., Mohan C., *Int Res J Pharm.* 2013, 4, 82
- [16] H. C. Patil, Patil I. M., Brose S. L, Pawar S. P, *World J Pharm Pharmaceut Sci.* 2015, 4:532
- [17] P. B. Mohite, Bhaskar V. H, *Int J PharmTech Res.*, 2011, 3, 1557
- [18] N. A. Kheder, S. M. Riyadh, A. M. Asiry, *Chem. Pharm. Bull.* 2013, 61 (5) 504–510.
- [19] Y. Naito, F. Akahoshi, S. Takeda, T. Okada, M. Kajii, H. Nishimura, M. Sugiura, C. Fukaya, Y. Kagitani, *J. Med. Chem.*, 1996, 39, 3019.
- [20] K. Okonogi and A. Tasaka, Can. Pat. Appl. CA 2 132 791 (*Chem. Abstr.*, 1996, 124, 8821t).
- [21] S. M. Kudari, S. M. Beede, W. Munera, *Asian J. Chem.*, 1997, 9, 20.
- [22] T. Denzel and H. Hoehn, U. S. Patent 1976, 3 971 801 (*Chem. Abstr.*, 1977, 86, P16675k).
- [23] A. H. El-Masry, H. H. Fahmy, S. H. Ali and A. S. Waheed, *Molecules*, 2000, 5, 1429.
- [24] A. S. Orabi, M. A. Moneim, E. E. Salem, M. E. Abdel-Fattah, *Polish J. Chem.*, 2000, 74, 1675.
- [25] A. Almasirad, S. A. Tabatabai, M. Faizi, A. Kebriaeezadeh, N. Mehrabi, A. Dalvandi and A. Shafiee, *Bioorg. Med. Chem Lett.*, 2004, 14, 6057.
- [26] T. George, D. Mehta, R. Tahilramani, J. David, P. Talwalker, *J. Med. Chem.*, 1971, 14, 335.
- [27] J. Bailey, *J. Chem. Soc. Perkin Trans. 1*, 1977, 2047.
- [28] T. Farghaly, M. Abdallah, G. Masaret, Z. Muhammad, *Eur. J. Med. Chem.*, 2015, 97, 320.
- [29] N. Abdel Hafez, T. Farghaly, M. Al-Omar, M. Abdalla, *Eur. J. Med. Chem.*, 2010, 45, 4838.
- [30] T. A. Farghaly and H. K. Mahmoud, *Arch. Pharm. Chem. Life Sci.*, 2013, 346, 392.
- [31] Girgis, A. S., Barsoum, F. F., Samir, A. *Eur. J. Med. Chem.* 2009, 44, 2447-2451.
- [32] Dalloul, H. M. *Arkivoc*, 2008 (xiv) 234-241.
- [33] Dalloul, H. M.; Abu samaha, A. *J Serb Chem. Soc.*, 2010, 75, 1473-1479.
- [34] Dalloul, H. M.; Boyle, P. H. *Heterocycl. Commun.* 2003, 9, 507-514.
- [35] Dalloul, H. M. *Chem. Heterocycl. Comp.* 2004, 40, 1402-1407.
- [36] Dalloul, H. M.; Boyle, P. H. *Turk. J. Chem.* 2006, 30, 119-124.
- [37] Dalloul, H. M.; Boyle, P. H. *Heterocycl. Commun.* 2007, 13, 155-160.
- [38] Thaher B. A.; Otto, H-H., *Monatsh. Chem.* 2002, 133, 1011-1016.
- [39] H. Hassaneen, Shawali, A., Elwan N., Abounada, N., *Sulfur Lett.* 1992, 13, 273-285.
- [40] H. Hassaneen, A. Shawali, N. Elwan, N. Abounada, *Org. Prep. Proced. Int.* 1992, 24, 171-175.
- [41] H. Dalloul, K. El-nwairy, A. Shorafa A. Abu Samaha, *South. Braz. J. Chem.* 2016, Accepted.
- [42] M. Okimoto, T. Chiba, *J. Org. Chem.*, 1990, 55, 1070.
- [43] H. M. Dalloul, *South. Braz. J. Chem.* 2015, 22, 17-26.
- [44] M. Hesse, H. Meier, B. Zech, *Spectroscopic Methods in Organic Chemistry*, George Thieme Verlag, Stuttgart, 1997, p. 229.